DK3377500T3 - Oxadiazaspiro-forbindelser til behandling af stofmisbrug og -afhængighed - Google Patents
Oxadiazaspiro-forbindelser til behandling af stofmisbrug og -afhængighed Download PDFInfo
- Publication number
- DK3377500T3 DK3377500T3 DK16797458.3T DK16797458T DK3377500T3 DK 3377500 T3 DK3377500 T3 DK 3377500T3 DK 16797458 T DK16797458 T DK 16797458T DK 3377500 T3 DK3377500 T3 DK 3377500T3
- Authority
- DK
- Denmark
- Prior art keywords
- dependence
- treatment
- drug abuse
- oxadiazaspiro
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382566 | 2015-11-16 | ||
| PCT/EP2016/001907 WO2017084752A1 (en) | 2015-11-16 | 2016-11-15 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3377500T3 true DK3377500T3 (da) | 2022-11-21 |
Family
ID=54707728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16797458.3T DK3377500T3 (da) | 2015-11-16 | 2016-11-15 | Oxadiazaspiro-forbindelser til behandling af stofmisbrug og -afhængighed |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US10927128B2 (da) |
| EP (1) | EP3377500B1 (da) |
| JP (1) | JP6884974B2 (da) |
| KR (2) | KR20250069710A (da) |
| CN (1) | CN108349999A (da) |
| AR (1) | AR106697A1 (da) |
| AU (1) | AU2016356488B2 (da) |
| CO (1) | CO2018004665A2 (da) |
| DK (1) | DK3377500T3 (da) |
| ES (1) | ES2932000T3 (da) |
| HR (1) | HRP20221343T1 (da) |
| HU (1) | HUE060275T2 (da) |
| IL (1) | IL259035B (da) |
| LT (1) | LT3377500T (da) |
| MA (1) | MA43250B1 (da) |
| MX (1) | MX384637B (da) |
| MY (1) | MY193423A (da) |
| PH (1) | PH12018500814A1 (da) |
| PL (1) | PL3377500T3 (da) |
| PT (1) | PT3377500T (da) |
| RS (1) | RS63734B1 (da) |
| SG (1) | SG11201803153RA (da) |
| SI (1) | SI3377500T1 (da) |
| SM (1) | SMT202200460T1 (da) |
| TN (1) | TN2018000122A1 (da) |
| TW (1) | TWI756196B (da) |
| UA (1) | UA123775C2 (da) |
| WO (1) | WO2017084752A1 (da) |
| ZA (1) | ZA201802845B (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10927128B2 (en) | 2015-11-16 | 2021-02-23 | Esteve Pharmaceuticals. S.A. | Oxadiazaspiro compounds for the treatment of drug abuse and addiction |
| WO2020157026A1 (en) * | 2019-01-28 | 2020-08-06 | Esteve Pharmaceuticals, S.A. | Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain |
| KR20240063904A (ko) | 2021-09-20 | 2024-05-10 | 에스테베 파마슈티칼스 에스에이 | 운동뉴런 변성 치료 또는 신경보호에 사용하기 위한 옥사디아자스피로 화합물 |
| WO2024105225A1 (en) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4244961A (en) * | 1978-10-26 | 1981-01-13 | Syntex (U.S.A.) Inc. | 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents |
| US4332804A (en) | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
| US4353900A (en) | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
| US4353901A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
| US6114541A (en) | 1997-03-10 | 2000-09-05 | Hoffmann-La Roche Inc. | Method for the preparation of α-Bromo-Lactam derivatives |
| JP2007522160A (ja) * | 2004-02-10 | 2007-08-09 | エフ．ホフマン−ラ ロシュ アーゲー | ケモカインｃｃｒ５受容体モジュレーター |
| ATE495730T1 (de) | 2004-03-03 | 2011-02-15 | Vital Health Sciences Pty Ltd | Alkaloid-formulierungen |
| EP1634873A1 (en) | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| EP1790639B1 (en) * | 2004-08-27 | 2014-03-26 | Ono Pharmaceutical Co., Ltd. | Spirocyclic compounds and their use as cxcr4-antagonists |
| CN101228127B (zh) * | 2005-05-30 | 2012-05-16 | Msdk.K.公司 | 哌啶衍生物 |
| CN101203567A (zh) * | 2005-06-07 | 2008-06-18 | 西巴特殊化学品控股有限公司 | 抗刮擦聚烯烃 |
| DE102005030051A1 (de) | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| PE20110285A1 (es) | 2005-10-19 | 2011-06-04 | Gruenenthal Chemie | Derivados de sulfonamidofenil propionamida como ligandos del receptor vaniloide del subtipo 1 |
| WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| EP1829869A1 (en) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands |
| EP1847542A1 (en) | 2006-04-21 | 2007-10-24 | Laboratorios del Dr. Esteve S.A. | Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor |
| WO2008105497A1 (ja) | 2007-03-01 | 2008-09-04 | Mitsubishi Tanabe Pharma Corporation | ベンゾイミダゾール化合物およびその医薬用途 |
| EP1982714A1 (en) | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Pyrano-pyrazole-amines |
| EP2020414A1 (en) * | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| US20110190280A1 (en) | 2007-08-29 | 2011-08-04 | George Adjabeng | Thiazole And Oxazole Kinase Inhibitors |
| EP2070933A1 (en) | 2007-12-07 | 2009-06-17 | Laboratorios del Dr. Esteve S.A. | Tricyclic triazolic compounds |
| PT2242759E (pt) | 2008-02-06 | 2012-12-17 | Astrazeneca Ab | Compostos |
| EP2108643A1 (en) * | 2008-04-10 | 2009-10-14 | Laboratorios Del. Dr. Esteve, S.A. | 4-methyl-4, 5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist |
| GB201016912D0 (en) * | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
| WO2013052716A1 (en) * | 2011-10-07 | 2013-04-11 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
| JPWO2013115294A1 (ja) * | 2012-01-31 | 2015-05-11 | 東レ株式会社 | ジアザスピロウレア誘導体及びその医薬用途 |
| WO2015017305A1 (en) | 2013-07-31 | 2015-02-05 | Merck Sharp & Dohme Corp | Inhibitors of the renal outer medullary potassium channel |
| TWI685497B (zh) * | 2014-06-02 | 2020-02-21 | 西班牙商伊史帝夫製藥公司 | 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物 |
| TW201615643A (zh) * | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物 |
| TW201615642A (zh) | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物 |
| US10513518B2 (en) * | 2015-01-29 | 2019-12-24 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US10927128B2 (en) | 2015-11-16 | 2021-02-23 | Esteve Pharmaceuticals. S.A. | Oxadiazaspiro compounds for the treatment of drug abuse and addiction |
-
2016
- 2016-11-15 US US15/774,407 patent/US10927128B2/en active Active
- 2016-11-15 AU AU2016356488A patent/AU2016356488B2/en active Active
- 2016-11-15 TN TNP/2018/000122A patent/TN2018000122A1/en unknown
- 2016-11-15 ES ES16797458T patent/ES2932000T3/es active Active
- 2016-11-15 UA UAA201806353A patent/UA123775C2/uk unknown
- 2016-11-15 KR KR1020257015708A patent/KR20250069710A/ko active Pending
- 2016-11-15 WO PCT/EP2016/001907 patent/WO2017084752A1/en not_active Ceased
- 2016-11-15 EP EP16797458.3A patent/EP3377500B1/en active Active
- 2016-11-15 DK DK16797458.3T patent/DK3377500T3/da active
- 2016-11-15 KR KR1020187017092A patent/KR20180080327A/ko not_active Ceased
- 2016-11-15 AR ARP160103486A patent/AR106697A1/es active IP Right Grant
- 2016-11-15 SM SM20220460T patent/SMT202200460T1/it unknown
- 2016-11-15 HU HUE16797458A patent/HUE060275T2/hu unknown
- 2016-11-15 LT LTEPPCT/EP2016/001907T patent/LT3377500T/lt unknown
- 2016-11-15 SG SG11201803153RA patent/SG11201803153RA/en unknown
- 2016-11-15 TW TW105137236A patent/TWI756196B/zh active
- 2016-11-15 HR HRP20221343TT patent/HRP20221343T1/hr unknown
- 2016-11-15 MX MX2018005439A patent/MX384637B/es unknown
- 2016-11-15 CN CN201680066748.9A patent/CN108349999A/zh active Pending
- 2016-11-15 MY MYPI2018701503A patent/MY193423A/en unknown
- 2016-11-15 PL PL16797458.3T patent/PL3377500T3/pl unknown
- 2016-11-15 SI SI201631621T patent/SI3377500T1/sl unknown
- 2016-11-15 PT PT167974583T patent/PT3377500T/pt unknown
- 2016-11-15 JP JP2018524257A patent/JP6884974B2/ja active Active
- 2016-11-15 RS RS20221052A patent/RS63734B1/sr unknown
- 2016-11-15 MA MA43250A patent/MA43250B1/fr unknown
-
2018
- 2018-04-16 PH PH12018500814A patent/PH12018500814A1/en unknown
- 2018-04-30 ZA ZA2018/02845A patent/ZA201802845B/en unknown
- 2018-04-30 IL IL259035A patent/IL259035B/en active IP Right Grant
- 2018-04-30 CO CONC2018/0004665A patent/CO2018004665A2/es unknown
-
2020
- 2020-12-21 US US17/128,738 patent/US11649248B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258931A (en) | Therapeutic compounds and methods | |
| DK3349758T3 (da) | Fremgangsmåder til behandling af arenaviridae-virusinfektioner | |
| DK3521282T3 (da) | Quinazolinderivater anvendt til behandling af hiv | |
| DK3173092T3 (da) | Rna-holdig sammensætning til behandling af tumorsygdomme | |
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3331915T3 (da) | Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3244948T3 (da) | Bestemmelse af medikamentdosis | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3307262T3 (da) | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3328864T3 (da) | Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3503890T3 (da) | Anvendelse af pridopidin til behandling af dystonier | |
| DK3099298T3 (da) | Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
| DK3710000T3 (da) | Tradipitant til anvendelse til behandling af gastroparese | |
| DK3324824T3 (da) | Fremgangsmåde til behandling af binokulare dysfunktioner | |
| DK3391902T3 (da) | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati |